By Counterforce Health Team in Tegsedi (inotersen) —

How to Get Tegsedi (Inotersen) Covered by Blue Cross Blue Shield of California: Complete Guide with Forms and Appeal Steps

Quick Answer: Getting Tegsedi Approved in California

Blue Cross Blue Shield of California requires prior authorization for Tegsedi (inotersen), REMS program enrollment, and ongoing lab monitoring. Most patients need to show first-line therapy failure before approval. If denied, California's Independent Medical Review (IMR) process offers strong appeal rights with no patient fees.

Your fastest path to approval:

  1. Confirm hATTR polyneuropathy diagnosis with genetic testing
  2. Document first-line treatment failures (Onpattro, Amvuttra)
  3. Submit prior authorization via Blue Shield's AuthAccel portal with REMS enrollment proof
  4. If denied, file internal appeal within 180 days, then request IMR through DMHC

Start today: Call Blue Shield member services (number on your ID card) to verify coverage and get current prior authorization forms.

Table of Contents

Understanding Tegsedi Coverage Requirements

Tegsedi (inotersen) is a specialty medication for hereditary transthyretin-mediated amyloidosis (hATTR) polyneuropathy that requires careful navigation of Blue Cross Blue Shield of California's coverage requirements.

Coverage at a Glance

Requirement What It Means Where to Find It Source
Prior Authorization Required for all plans Blue Shield AuthAccel Portal Blue Shield PA List
REMS Enrollment FDA-mandated safety program Tegsedi REMS Program FDA Requirements
Step Therapy First-line treatments must fail first Plan formulary Blue Shield Specialty Drug List
Specialty Pharmacy Must use in-network specialty pharmacy Blue Shield Pharmacy Network Network Directory
Lab Monitoring Ongoing platelet and kidney function tests REMS protocol FDA REMS Requirements

Diagnosis Requirements

Your doctor must confirm hATTR polyneuropathy through:

  • Genetic testing showing pathogenic TTR mutation
  • Clinical symptoms of progressive sensorimotor neuropathy
  • ICD-10 code E851 for polyneuropathy of hereditary transthyretin-mediated amyloidosis

Blue Cross Blue Shield of California typically covers medically necessary genetic testing when there's clinical suspicion based on symptoms or family history.

Step-by-Step: Fastest Path to Approval

1. Confirm Diagnosis and Eligibility

Who does it: Your doctor
Documents needed: Genetic test results, clinical notes
Timeline: 1-2 weeks for genetic testing results

Your physician must document hATTR polyneuropathy with genetic confirmation of a pathogenic TTR variant. This typically requires blood testing that takes 10-21 days for results.

2. Document First-Line Treatment Failures

Who does it: Your doctor
Documents needed: Treatment history, adverse reaction notes
Timeline: Ongoing documentation

Blue Cross Blue Shield requires step therapy, meaning you must try first-line treatments like patisiran (Onpattro) or vutrisiran (Amvuttra) first. Your doctor needs to document why these treatments failed, weren't tolerated, or are contraindicated.

3. Enroll in Tegsedi REMS Program

Who does it: You and your doctor
Documents needed: REMS enrollment forms
Timeline: 1-3 business days

Both you and your prescribing physician must enroll in the FDA-mandated REMS program before Tegsedi can be dispensed. This includes safety training and monitoring requirements.

4. Complete Baseline Laboratory Tests

Who does it: You (lab work)
Documents needed: Lab results
Timeline: 1-2 days

Required baseline tests include:

  • Platelet count (must be ≥100 x 10⁹/L)
  • Serum creatinine and urine protein
  • Liver function tests

5. Submit Prior Authorization Request

Who does it: Your doctor's office
How to submit: Blue Shield AuthAccel portal or fax
Timeline: 5-14 business days for determination

The prior authorization packet should include:

  • Completed PA form
  • Clinical notes supporting diagnosis
  • Genetic test results
  • Documentation of first-line treatment failures
  • REMS enrollment confirmation
  • Recent lab results

6. Coordinate with Specialty Pharmacy

Who does it: You and your doctor
Timeline: 1-3 business days after approval

Tegsedi must be dispensed through Blue Shield's in-network specialty pharmacy, typically CVS Specialty. They'll coordinate delivery and provide injection training.

7. Begin Ongoing Monitoring

Who does it: You and your doctor
Timeline: Weekly initially, then every 2 weeks

REMS requires regular monitoring:

  • Platelet counts weekly for first 8 weeks, then every 2 weeks
  • Kidney function tests every 2 weeks
  • Regular clinical assessments

Common Denial Reasons & How to Fix Them

Denial Reason How to Overturn Required Documents
No REMS enrollment Submit proof of enrollment REMS enrollment confirmation
Step therapy not completed Document first-line failures Treatment history, adverse reactions
Insufficient lab monitoring plan Provide monitoring schedule Lab monitoring protocol
Diagnosis not confirmed Submit genetic testing TTR gene mutation results
Not medically necessary Strengthen clinical justification Detailed medical necessity letter

Appeals Playbook for Blue Cross Blue Shield California

If your initial request is denied, California offers robust appeal rights through both Blue Shield and state regulators.

Internal Appeal Process

Timeline: File within 180 days of denial notice
Decision timeframe: 30 days for standard, 72 hours for expedited
How to file: Blue Shield member portal or written request

Include in your appeal:

  • Original denial letter
  • Additional medical records
  • Updated lab results
  • Peer-reviewed literature supporting Tegsedi use

California Independent Medical Review (IMR)

If Blue Shield upholds the denial, California residents can request an Independent Medical Review through the Department of Managed Health Care (DMHC).

Eligibility: Denials based on medical necessity or experimental/investigational determinations
Cost: Free to patients
Timeline: 30-45 days for standard review, 3-7 days for expedited
How to apply: DMHC online application or call 1-888-466-2219

From our advocates: We've seen several Tegsedi appeals succeed at the IMR level when patients provided comprehensive documentation of hATTR progression despite first-line treatments, along with peer-reviewed evidence supporting inotersen's efficacy. The key is presenting a complete clinical picture that clearly demonstrates medical necessity.

IMR Success Factors:

  • Complete medical records showing disease progression
  • Documentation of treatment failures or contraindications
  • Supporting literature from medical journals
  • Clear explanation of why Tegsedi is medically necessary

Clinician Corner: Medical Necessity Documentation

Medical Necessity Letter Checklist

A strong medical necessity letter should include:

Patient Background:

  • Confirmed hATTR polyneuropathy diagnosis with genetic testing results
  • Disease severity and progression timeline
  • Impact on daily functioning and quality of life

Treatment History:

  • Detailed documentation of first-line therapy trials
  • Specific reasons for treatment failures (lack of efficacy, adverse reactions)
  • Any contraindications to preferred agents

Clinical Rationale:

  • Why Tegsedi is medically necessary for this patient
  • Expected clinical benefits
  • Monitoring plan for safety parameters

Supporting Evidence:

  • FDA prescribing information for Tegsedi
  • Relevant clinical trial data
  • Professional society guidelines (when available)

Key Clinical Citations

  • FDA Label: Tegsedi prescribing information includes efficacy data from the NEURO-TTR study
  • REMS Requirements: Detailed safety monitoring protocols available through the Tegsedi REMS program
  • Genetic Testing Guidelines: Professional societies provide recommendations for TTR genetic testing in suspected hATTR cases

Patient Assistance and Specialty Pharmacy

Financial Assistance Options

Manufacturer Support: Ionis Pharmaceuticals may offer patient assistance programs for eligible patients. Contact their patient support services to inquire about:

  • Copay assistance programs
  • Patient assistance programs for uninsured/underinsured patients
  • Free drug programs based on financial need

Foundation Grants: Several nonprofit organizations provide grants for specialty medications. Your specialty pharmacy can help identify potential sources of assistance.

Specialty Pharmacy Requirements

Tegsedi must be dispensed through Blue Shield's in-network specialty pharmacy network. These pharmacies provide:

  • Prior authorization coordination
  • Insurance benefit verification
  • Patient education and injection training
  • Ongoing clinical monitoring support
  • Coordination with your healthcare team

Key Specialty Pharmacy Services:

  • Home delivery of medication
  • Injection training and supplies
  • 24/7 clinical support
  • Assistance with insurance appeals
  • Coordination of lab monitoring

Frequently Asked Questions

How long does Blue Cross Blue Shield prior authorization take in California? Standard prior authorization decisions are typically made within 5-14 business days. Expedited requests for urgent medical situations are decided within 72 hours.

What if Tegsedi is not on my formulary? You can request a formulary exception through Blue Shield's prior authorization process. Provide strong clinical justification for why Tegsedi is medically necessary despite not being a preferred drug.

Can I request an expedited appeal? Yes, if your health would be seriously jeopardized by delays in treatment. Both Blue Shield and California's IMR process offer expedited reviews for urgent situations.

Does step therapy apply if I tried treatments outside California? Yes, treatment history from other states counts toward step therapy requirements. Provide documentation of all previous treatments and outcomes.

What happens if Blue Shield denies my appeal? California residents can request an Independent Medical Review through DMHC. This is a free, binding external review by independent medical experts.

How often do IMRs overturn specialty drug denials? While specific success rates for Tegsedi aren't publicly available, California's IMR process has historically shown favorable outcomes for medically justified specialty drug appeals when proper documentation is provided.

Can I use any specialty pharmacy? No, you must use a specialty pharmacy in Blue Shield's network. Using an out-of-network pharmacy will result in no coverage or significantly higher costs.

What if I can't afford the copay? Contact the manufacturer's patient assistance program and ask your specialty pharmacy about foundation grants and other financial assistance options.

When to Escalate: Getting Additional Help

If you're struggling with the appeals process, California offers several resources:

DMHC Help Center: 1-888-466-2219
Free assistance with filing complaints and IMR applications

Health Consumer Alliance: Nonprofit organization providing free help with insurance appeals

California Department of Insurance: For plans regulated by CDI rather than DMHC

Counterforce Health specializes in turning insurance denials into successful appeals by creating targeted, evidence-backed submissions that align with payer requirements. Our platform helps patients, clinicians, and specialty pharmacies navigate complex prior authorization and appeals processes for specialty medications like Tegsedi.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Insurance coverage policies change frequently. Always verify current requirements with Blue Cross Blue Shield of California and consult with your healthcare provider about treatment decisions. For personalized assistance with insurance appeals and prior authorization, visit www.counterforcehealth.org.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.